Growth Disorders Completed Phase 2 Trials for PIK3CA (DB14954)

Also known as: Growth Disorder

IndicationStatusPhase
DBCOND0028940 (Growth Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02428296Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K ActivationTreatment